Clinical integration of machine learning for curative-intent radiation treatment of patients with prostate cancer.

Journal: Nature medicine
Published Date:

Abstract

Machine learning (ML) holds great promise for impacting healthcare delivery; however, to date most methods are tested in 'simulated' environments that cannot recapitulate factors influencing real-world clinical practice. We prospectively deployed and evaluated a random forest algorithm for therapeutic curative-intent radiation therapy (RT) treatment planning for prostate cancer in a blinded, head-to-head study with full integration into the clinical workflow. ML- and human-generated RT treatment plans were directly compared in a retrospective simulation with retesting (n = 50) and a prospective clinical deployment (n = 50) phase. Consistently throughout the study phases, treating physicians assessed ML- and human-generated RT treatment plans in a blinded manner following a priori defined standardized criteria and peer review processes, with the selected RT plan in the prospective phase delivered for patient treatment. Overall, 89% of ML-generated RT plans were considered clinically acceptable and 72% were selected over human-generated RT plans in head-to-head comparisons. RT planning using ML reduced the median time required for the entire RT planning process by 60.1% (118 to 47 h). While ML RT plan acceptability remained stable between the simulation and deployment phases (92 versus 86%), the number of ML RT plans selected for treatment was significantly reduced (83 versus 61%, respectively). These findings highlight that retrospective or simulated evaluation of ML methods, even under expert blinded review, may not be representative of algorithm acceptance in a real-world clinical setting when patient care is at stake.

Authors

  • Chris McIntosh
  • Leigh Conroy
    Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Michael C Tjong
    Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Tim Craig
    Radiation Medicine Program, UHN Princess Margaret Cancer Centre, 610 University of Avenue, Toronto, Ontario M5T 2M9, Canada and Department of Radiation Oncology, University of Toronto, 148 - 150 College Street, Toronto, Ontario M5S 3S2, Canada.
  • Andrew Bayley
    Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Charles Catton
    Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Mary Gospodarowicz
    Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Joelle Helou
    Department of Radiation Oncology, Odette Cancer Center, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
  • Naghmeh Isfahanian
    Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Vickie Kong
    Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Tony Lam
    Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Srinivas Raman
    Department of Radiation Oncology, BC Cancer Vancouver, 600 W 10th Ave, Vancouver, BC, V5Z 4E6, Canada, 1 416-946-4501.
  • Padraig Warde
    Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Peter Chung
    Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Alejandro Berlin
    Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Thomas G Purdie
    Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario M5G 2M9, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Ontario M5S 3E2, Canada; and Techna Institute, University Health Network, Toronto, Ontario M5G 1P5, Canada.